Genmab Reports Updated Petosemtamab Phase 2 Follow-Up Analyses

Genmab announced updated follow-up analyses from a Phase 2 trial of investigational petosemtamab in combination. The headline reports meaningful objective response rates in patients with metastatic colorectal cancer.